管理肾移植患者恶性肿瘤的新概念。
Emerging Concepts in Managing Malignancy in Kidney Transplant Patients.
机构信息
Transplant Research Center, Renal Division, Brigham and Women's Hospital, Boston, Massachusetts.
Institute for Academic Medicine, Weill Cornell Medical College, Houston Methodist Cancer Center, Houston, Texas; Cockrell Center of Advanced Therapeutics Phase I Program, Houston Methodist Research Institute, Houston, Texas.
出版信息
Semin Nephrol. 2022 Jan;42(1):63-75. doi: 10.1016/j.semnephrol.2022.01.003.
Abstract
Cancer remains a significant cause of morbidity and mortality in kidney transplant recipients, due to long-term immunosuppression. Salient issues to consider in decreasing the burden of malignancy among kidney transplant recipients include pretransplant recipient evaluation, post-transplant screening and monitoring, and optimal treatment strategies for the kidney transplant recipients with cancer. In this review, we address cancer incidence and outcomes, approaches to cancer screening and monitoring pretransplant and post-transplant, as well as treatment strategies, immunosuppressive management, and multidisciplinary approaches in the kidney transplant recipients with cancer.
摘要
癌症仍然是导致肾移植受者发病率和死亡率的重要原因，这是由于长期免疫抑制。为了降低肾移植受者恶性肿瘤的负担，需要考虑一些突出的问题，包括移植前受者评估、移植后筛查和监测，以及对患有癌症的肾移植受者的最佳治疗策略。在这篇综述中，我们讨论了癌症的发病率和结果、移植前和移植后的癌症筛查和监测方法，以及患有癌症的肾移植受者的治疗策略、免疫抑制管理和多学科方法。
相似文献
1
Emerging Concepts in Managing Malignancy in Kidney Transplant Patients.管理肾移植患者恶性肿瘤的新概念。
Semin Nephrol. 2022 Jan;42(1):63-75. doi: 10.1016/j.semnephrol.2022.01.003.
2
Malignancies in adult kidney transplant candidates and recipients: current status.成人肾移植候选人和受者的恶性肿瘤：现状。
Nephrol Dial Transplant. 2023 Jun 30;38(7):1591-1602. doi: 10.1093/ndt/gfac239.
3
Epidemiology of Cancer in Kidney Transplant Recipients.肾移植受者的癌症流行病学
Semin Nephrol. 2024 Jan;44(1):151494. doi: 10.1016/j.semnephrol.2024.151494. Epub 2024 Mar 27.
4
Malignancy in kidney transplant recipients.肾移植受者中的恶性肿瘤
Drugs. 2008;68 Suppl 1:11-9. doi: 10.2165/00003495-200868001-00003.
5
Pediatric Kidney Transplantation: Cancer and Cancer Risk.小儿肾移植：癌症与癌症风险
Semin Nephrol. 2024 Jan;44(1):151501. doi: 10.1016/j.semnephrol.2024.151501. Epub 2024 Apr 4.
6
Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis.移植前接受免疫抑制治疗肾小球肾炎的肾移植受者的恶性肿瘤风险。
Nephrol Dial Transplant. 2023 Aug 31;38(9):2009-2018. doi: 10.1093/ndt/gfac337.
7
Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.心脏和肾脏移植患者的移植后淋巴细胞增生性疾病：单中心经验
J Cardiovasc Pharmacol Ther. 2006 Mar;11(1):77-83. doi: 10.1177/107424840601100107.
8
Impact of Immunosenescence in Older Kidney Transplant Recipients: Associated Clinical Outcomes and Possible Risk Stratification for Immunosuppression Reduction.老年肾移植受者免疫衰老的影响：相关临床结局及免疫抑制减少的可能风险分层。
Drugs Aging. 2024 Mar;41(3):219-238. doi: 10.1007/s40266-024-01100-5. Epub 2024 Feb 22.
9
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.器官移植受者的免疫抑制治疗与恶性肿瘤：一项系统综述
Drugs. 2007;67(8):1167-98. doi: 10.2165/00003495-200767080-00006.
10
COVID-19 in kidney transplant recipients: A multicenter experience in Istanbul.肾移植受者中的新型冠状病毒肺炎：伊斯坦布尔的多中心经验
Transpl Infect Dis. 2020 Oct;22(5):e13371. doi: 10.1111/tid.13371. Epub 2020 Jul 13.
引用本文的文献
1
Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits.肾移植患者的癌症免疫治疗：风险与益处之间的艰难平衡
Transpl Int. 2024 Nov 25;37:13204. doi: 10.3389/ti.2024.13204. eCollection 2024.
2
Post-Kidney Transplant Cancer: A Real-World Retrospective Analysis From a Single Italian Center.肾移植后癌症：来自意大利单中心的真实世界回顾性分析。
Transpl Int. 2024 Aug 20;37:13220. doi: 10.3389/ti.2024.13220. eCollection 2024.
3
Report on post-transplantation cancer in southeast Asia from the Thai kidney transplantation cohort.东南亚器官移植后癌症报告：来自泰国肾脏移植队列的研究。
Sci Rep. 2024 Aug 30;14(1):20154. doi: 10.1038/s41598-024-71041-x.
4
Transplant Onconephrology in Patients With Kidney Transplants.移植肾肿瘤学在肾移植患者中的应用。
Adv Chronic Kidney Dis. 2022 Mar;29(2):188-200.e1. doi: 10.1053/j.ackd.2021.09.002.
本文引用的文献
1
Safety of CAR T-cell therapy in kidney transplant recipients.肾移植受者中CAR T细胞疗法的安全性。
Blood. 2021 May 6;137(18):2558-2562. doi: 10.1182/blood.2020008759.
2
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.免疫检查点抑制剂在肾移植癌症患者中的安全性和疗效的多中心研究。
Kidney Int. 2021 Jul;100(1):196-205. doi: 10.1016/j.kint.2020.12.015. Epub 2020 Dec 24.
3
Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decades.多发性骨髓瘤患者的肾移植：叙事分析和过去二十年的回顾。
Nephrol Dial Transplant. 2022 Aug 22;37(9):1616-1626. doi: 10.1093/ndt/gfaa361.
4
Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series.抗 CD19 CAR-T 疗法治疗 EBV 阴性移植后淋巴组织增生性疾病：单中心病例系列。
Bone Marrow Transplant. 2021 May;56(5):1031-1037. doi: 10.1038/s41409-020-01145-1. Epub 2020 Nov 23.
5
Advancing Palliative Care in Patients With CKD: From Ideas to Practice.推进慢性肾脏病患者的姑息治疗：从理念到实践。
Am J Kidney Dis. 2021 Mar;77(3):420-426. doi: 10.1053/j.ajkd.2020.09.012. Epub 2020 Nov 9.
6
Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients.氢氯噻嗪的使用与肾移植受者角质形成细胞癌风险的关联。
Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1804-1813. doi: 10.2215/CJN.02560220. Epub 2020 Nov 10.
7
Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period.美国三十年来肾移植受者癌症发病率和结局的变化。
Kidney Int. 2021 Jun;99(6):1430-1438. doi: 10.1016/j.kint.2020.10.018. Epub 2020 Nov 5.
8
CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.嵌合抗原受体 T 细胞疗法治疗移植后难治性淋巴增殖性疾病的实体器官移植受者。
Am J Transplant. 2021 Feb;21(2):809-814. doi: 10.1111/ajt.16367. Epub 2020 Dec 5.
9
Balancing uncertain risks in candidates for solid organ transplantation with a history of malignancy: Who is safe to transplant?平衡有恶性肿瘤病史的实体器官移植受者的不确定风险：谁适合进行移植？
Am J Transplant. 2021 Feb;21(2):447-448. doi: 10.1111/ajt.16366. Epub 2020 Nov 10.
10
Association of Receipt of Palliative Care Interventions With Health Care Use, Quality of Life, and Symptom Burden Among Adults With Chronic Noncancer Illness: A Systematic Review and Meta-analysis.接受姑息治疗干预与慢性非癌症疾病成人的医疗保健使用、生活质量和症状负担的关联：系统评价和荟萃分析。
JAMA. 2020 Oct 13;324(14):1439-1450. doi: 10.1001/jama.2020.14205.
Zotero 插件